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Finding novel, eﬀ  ective, Alzheimer’s disease (AD) thera-
peutics has emerged as one of the major unmet medical 
needs in most developed nations [1,2]. AD is quite 
unique among highly prevalent diseases within these 
nations in that, despite tremendous advances in under-
standing certain aspects of AD pathogenesis, there are no 
proven disease-modifying therapies and only minimally 
eﬀ   ective symptomatic therapies. Th  ough many other 
prevalent diseases still cause tremendous morbidity and 
mortality, for many of them scientiﬁ   c and medical 
advances have led to novel therapies that alter disease 
course, reduce mortality, or at least signiﬁ  cantly relieve 
symptoms for some period of time. Typically, these 
therapies are not panaceas, or true cures, but nevertheless 
signiﬁ  cant therapeutic inroads have been made.
Perhaps the most striking example of recent success in 
curbing a major emerging epidemic is HIV/AIDS. Within 
two decades of the identiﬁ  cation of HIV as the cause of 
AIDS, rapid development of multiple anti-viral therapies 
turned a rapidly progressive and fatal disease into a more 
chronic disease, at least in industrialized nations [3,4]. Of 
course, there are no widely deployable cures yet for HIV/
AIDs, and it is still a potentially lethal disease. Moreover, 
anti-viral pharmacotherapy needed to control disease 
progression has numerous and signiﬁ   cant side eﬀ  ects. 
Nevertheless, given the continued progress, there is 
reasonable hope that either prophylaxis with vaccines or 
further advances in anti-viral therapies will further 
reduce or eliminate HIV-related morbidity and mortality. 
Notably, the historical timelines for discovery of the 
presumed causative agents of HIV and AD are similar, 
with HIV deﬁ  nitively identiﬁ  ed in 1981 and the suspected 
protein triggers of AD identiﬁ  ed in the mid-1980s, with 
strong links to causality established for amyloid beta (Aβ) 
and tau aggregates established in the 1990s.
Given this interesting parallel in timelines for HIV/
AIDs and AD, it is worthwhile to explore the question: 
“Why have we not made more inroads with respect to 
disease-modifying therapeutics for AD?” Th  is question 
needs to be asked in the context of the question: “What 
factors were enabling in the development of novel anti-
HIV therapies?” Although there are certainly many 
germane medical and scientiﬁ  c issues, one critical aspect 
may simply be that the funding for HIV/AIDs research, at 
least in the United States, appears to have been suﬃ   cient, 
and therefore in retrospect “right sized”, to enable not only 
basic understanding of the disease-causing entity and the 
disease it causes but also to translate that enhanced 
understanding into novel and eﬀ  ective therapeutics.
If one assumes that funding for HIV/AIDS was right 
sized to enable translation of basic discoveries to success-
ful therapies, then given the lack of eﬀ  ective  AD 
therapies, one possible implication is that funding for AD 
has been insuﬃ     cient. A quick comparison of funding 
levels for HIV/AIDs relative to AD in the United States 
suggests this may be at least one factor that has hindered 
the translation of AD discovery to eﬀ  ective therapies. 
Based on publicly available data, National Institute of 
Health funding for HIV/AIDS in the United States is 
currently approximately $3 billion [5]. With approxi-
mately 1 million HIV-positive subjects in the United 
States, this equates to $3,000 of NIH funding per person 
with HIV/AIDs. In contrast, current NIH funding for AD 
is at a level of approximately $450 million [5], with perhaps 
another approximately $100 million to $200 million in 
NIH funding that might have some relevance to the study 
of AD (cognitive decline in aging, related neuro  degenera-
tive conditions). With a current prevalence of approxi-
mately 5 million individuals aﬀ   ected with AD in the 
United States, this equates to a maximum of $130 of NIH 
funding per person aﬀ  ected with the disease. So, on a per 
aﬀ  ected individual basis, NIH funding for HIV/AIDs is 
23 times the level of that for AD.
Of course, there are many diﬀ  erent ways to evaluate 
proportional or relative funding. Another one that is 
quite germane is economic impact. For AD in the United 
States this is estimated at more than $170 billion per year 
(and worldwide at $600 billion per year) [6]. Again 
focusing only on the United States, the yearly funding for 
research by the NIH represents 0.4% of the yearly costs of 
the disease in the United States. In other words, for every 
$2 the disease costs the United States, we spend less than 
1 cent on research. © 2010 BioMed Central Ltd
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attempt to determine the amount of research dollars 
relative to disease prevalence or impact. First, only 
looking at funding from the NIH provides a sim  plistic 
view of the funds spent to support AD research, or for 
that matter, any research directed towards any given 
disease. Th  ere are many private foundations, other 
signiﬁ  cant public sector funds, both in the United States 
and other countries, and private sector funds devoted to 
AD research, as well as the eﬀ   orts of pharmaceutical 
companies in drug discovery. Th   ere are many challenges 
to collating this funding, however, and it is generally 
acknowledged that, with few exceptions, the NIH is the 
largest single source of research support. Th  us, NIH 
funding is often a reasonable benchmark, and one of the 
few transparent ones that can be used to compare relative 
investments in research for a given disease. Second, there 
will be bias in these ﬁ   gures whether one focuses on 
incidence, prevalence, morbidity, mortality, or economic 
impact. All of these factors contribute in overlapping 
ways to what might be considered as the societal impact 
of the disease, and depending on one’s own perspective, 
one might weigh these various factors diﬀ  erently. Indeed, 
most advocacy groups for any given disease will tend to 
provide data that are most supportive of advancing their 
cause.
Funding levels for research on any disease have legacies 
that have evolved over time and can potentially be attri-
butable to a plethora of complex factors. Likely major 
inﬂ  uences on public sector funding for various disease 
entities are: a combination of the aforementioned objec-
tive and subjective measures of disease burden; societal 
pressures from either individual or group-based advo-
cacies for research into a given disease; and perception or 
promise of ability to impact a given disease process. 
Many other factors that are less tangible, such as pure 
academic interest or perceived threat to future welfare, 
also contribute. Until recently, private sector funding has 
largely been driven by potential return on investment, 
with funding focused on therapeutic discovery and 
development programs for major diseases with deﬁ  ned 
and potentially druggable targets.
Clearly, as described above, current measures of 
disease burden for AD suggest that it is underfunded. 
Moreover, at least in recent years, numerous advocacy 
groups have increased eﬀ  orts to raise awareness of the 
societal and economic impact of AD, but to date this has 
failed to translate into signiﬁ   cantly increased research 
funding. As to why these advocacy eﬀ   orts have not 
resulted in enhanced funding is diﬃ   cult to pinpoint, but 
might speculatively be attributable to several factors. 
First, AD is a disease of the elderly, and until recently was 
not universally accepted as a disease entity, but to some 
considered to be an inevitable consequence of aging. Th  is 
lack of clarity regarding nosology, the sense of 
inevitability, as well as the diminished social stature of 
the elderly, at least in the United States, may all have 
undercut eﬀ   orts to increase AD research funding. 
Another aspect of advocacy is that AD patients, due to 
the consequences of the disease process, tend not to be 
good spokespersons. Th   e nature of AD limits the ability 
of an aﬀ   ected person to articulate their experience, 
particularly as the illness progresses. Unlike HIV or 
cancer, there are no AD survivors, with compelling 
narratives of struggle and success. Consider, in contrast, 
Michael J Fox and his advocacy on behalf of Parkinson’s 
disease [7]. Mr Fox can speak eloquently about the 
impact of his disease in public. Not only does he speak 
eloquently but he concurrently displays the debilitating 
motor symptoms characteristic of Parkinson’s disease 
while he is advocating for more research funding. 
Notably, spouses and caregivers of AD patients are often 
so consumed with care giving that they simply do not 
have the time to devote to raising awareness of the 
disease and the need for more funding. Indeed, personal 
stories of caregivers can be incredibly eﬀ  ective but most 
often when they tangibly illustrate the eﬀ   ects of the 
disease on the patient (see, for example, Judith Fox 
talking about her ongoing eﬀ   orts on behalf of her 
husband who has AD [8]), but rarely receive the same 
level of publicity as seen in many other diseases. Note-
worthy exceptions in the United States regarding 
attempts to raise public awareness have been the recent 
ongoing reporting by the New York Times on AD, AD 
research and its personal and societal impact, Maria 
Shriver’s Annual Report, the Alzheimer Breakthrough 
ride and ongoing eﬀ  orts by the Alzheimer’s Association.
A ﬁ  nal factor in deﬁ  ning public sector funding levels, 
and certainly the paramount one for private sector 
funding, is whether there is a potential to not only gain 
an enhanced understanding of the disease but also to 
translate that into eﬀ  ective therapies. Typically, though 
not always, one needs a mechanistic understanding of the 
disease in order to treat it. Although there is much work 
left to do, major transformative advances in deﬁ  ning the 
mechanistic underpinnings of AD have led to novel 
thera  peutic target identiﬁ  cation. So with the recognition 
that, in general, developing new therapies for central 
nervous system disease poses unique challenges and that, 
as highlighted in a recent review, many current AD 
therapies may be being tested in the wrong patient popul-
ations (for example, anti-Aβ therapies in patients with 
symptomatic AD), there is abundant evidence that AD is 
likely to be a preventable if not treatable disease [9].
Given this last assertion that we are potentially on the 
verge of making breakthroughs with respect to new AD 
therapies, one might question whether additional 
incremental funding is needed. Indeed, historical funding 
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substantial scientiﬁ  c advances. However, these scientiﬁ  c 
advances must be translated and the translational eﬀ  orts 
are extremely expensive. In the current environment of 
relatively unchanged or slightly decreasing NIH and 
general public sector funding, there is a great concern 
among AD investigators that these necessary and expen-
sive translational eﬀ  orts will further erode funding for 
more basic discovery research. And, though we do know 
a lot more about AD than we did 25 years ago, there are a 
number of fundamental questions we do not know the 
answers to that have direct therapeutic relevance [10]. 
Moreover, there are also concerns that optimal design for 
translational work (clinical therapeutic trials, longitudinal 
biomarker studies) may be compromised due to budget-
ary constraints. Current levels of funding may reduce the 
number of therapeutic trials that can be conducted or the 
number of individuals within a given trial, thereby 
limiting our ability to identify optimal therapeutic agents. 
Also, long-term trials studying intervention to either 
prevent AD pathology from developing or from progres-
sing to cause early symptoms will require a sustainable 
long-term increase in funding.
To conclude, there are no easy answers to the question 
regarding right sizing funding for AD. Based on argu-
ments presented here, we would simply say that public 
sector investment in AD research is far too small and that 
targets such as proposed in the Alzheimer’s Breakthrough 
Act of $2 billion per year of NIH funding would likely be 
transformative. Similar increases in public sector AD 
research funding in other industrialized nations would 
obviously have great impact as well. Th  ough for most 
endeavors there is a point where beneﬁ  ts of increased 
investment yield increasingly poorer returns, we would 
argue that we are far from this scenario in AD. Current 
funding levels are restricting promising research and 
driving investigators to pursue other lines of research. As 
bolus increases can sometimes be misdirected, we would 
suggest a stepwise increase in NIH funding for AD 
research of 15 to 20% per year until the $2 billion target is 
reached or it is clear that the hoped-for breakthroughs 
are imminent and achievable given some future funding 
level. We must all advocate for additional funding to 
support our collective ﬁ   ght against AD, and in the 
meantime continue to use our resources as wisely as 
possible to ensure that we advance our understanding of 
this devastating disease and translate that understanding 
into eﬀ  ective therapies.
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